Twist Bioscience (NASDAQ:TWST) CEO Sells 5,203 Shares of Company Stock

Twist Bioscience Corporation (NASDAQ:TWST) CEO Emily Leproust sold 5,203 shares of the company’s stock in a transaction on Thursday, September 24th. The shares were sold at an average price of $177.38, for a total transaction of $922,908.14. Following the transaction, the chief executive officer owned 613,699 shares of the company’s stock, valued at approximately $108,857,928.62. The trade was a 0.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Twist Bioscience Trading Down 0.7%

TWST traded down $1.20 during mid-day trading on Friday, reaching $182.83. The stock had a trading volume of 2,689,406 shares, compared to its average volume of 1,580,441. The firm’s fifty day simple moving average is $125.11 and its two-hundred day simple moving average is $86.46. The stock has a market capitalization of $11.47 billion, a P/E ratio of -82.36 and a beta of 2.22. Twist Bioscience Corporation has a 52 week low of $23.30 and a 52 week high of $186.20. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). The business had revenue of $118.38 million during the quarter, compared to analyst estimates of $114.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. Twist Bioscience’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same quarter last year, the business earned $0.33 earnings per share. On average, equities analysts predict that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Institutional Investors Weigh In On Twist Bioscience

A number of institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. acquired a new position in Twist Bioscience during the 2nd quarter valued at about $600,191,000. William Blair Investment Management LLC acquired a new position in Twist Bioscience during the second quarter valued at approximately $223,722,000. Bank of America Corp DE acquired a new stake in shares of Twist Bioscience in the second quarter worth $94,922,000. Allspring Global Investments Holdings LLC acquired a new position in shares of Twist Bioscience in the first quarter valued at $22,563,000. Finally, BNP Paribas Financial Markets lifted its position in shares of Twist Bioscience by 242.2% during the 4th quarter. BNP Paribas Financial Markets now owns 415,609 shares of the company’s stock worth $13,183,000 after buying an additional 294,144 shares during the period.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on TWST. Leerink Partners boosted their price target on shares of Twist Bioscience from $120.00 to $160.00 and gave the stock an “outperform” rating in a report on Thursday, September 17th. Piper Sandler lifted their price objective on Twist Bioscience from $85.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday, August 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a report on Monday. Robert W. Baird upped their price objective on Twist Bioscience from $113.00 to $115.00 and gave the company an “outperform” rating in a research report on Tuesday, August 4th. Finally, Barclays increased their price target on Twist Bioscience from $65.00 to $95.00 and gave the company an “overweight” rating in a report on Wednesday, June 24th. Eight investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $103.00.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA using a proprietary silicon-based platform. The company serves researchers and organizations in biotechnology, pharmaceutical development, agriculture, industrial chemicals and academic research.

Its products include synthetic genes, gene fragments, oligonucleotides and DNA libraries used in research, drug discovery, diagnostics development and other applications. Twist also provides next-generation sequencing tools and products, including target-enrichment and sample-preparation solutions, as well as synthetic biology services that support the design and testing of biological systems.

Twist was founded in 2013 and is headquartered in South San Francisco, California.